UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________to____________ Commission file number: 001-40492 Femasys Inc. (Exact Name of Registrant as Specified in its Charter) | --- | --- | |--------------- ...

Exhibit 99.1 Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update -- Company gained CE Mark approval for four of its women's health products and completed buildout of commercial team for its infertility portfolio -- ATLANTA, August 8, 2024 -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, a ...

ATLANTA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of inoffice, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended June 30, 2024 and provides a corporate update. Corporate Highlights from 2Q 2024 to date Company received European Union Medical Device Regulation (EU MDR) certification and CE Mark for four of its ...

ATLANTA, June 27, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of inoffice, accessible, and innovative therapeutic and diagnostic products, announces it will be participating at the European Society of Human Reproduction and Embryology's (ESHRE) 40th Annual Meeting in Amsterdam on July 7-10. The Company will be exhibiting at booth #11,111. The conference follows Femasys receiving C ...

The conference follows Femasys receiving CE Mark certification for four of its products – FemaSeed®, FemVue®, FemCerv®, and FemCath® – making them compliant with the new European Union legislation for medical devices and approved for commercial sale. ESHRE is focused on promoting awareness and knowledge around infertility and reproductive care, aiming to provide members and beyond a holistic understanding of reproductive biology and medicine. The ESHRE Annual Meeting is being held at the RAI Amsterdam and w ...

ATLANTA, June 20, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of inoffice, accessible, and innovative therapeutic and diagnostic products, announces it has received its European Union Medical Device Regulation (EU MDR) certificate and CE Mark certification for four of its products. The four products – FemaSeed®, FemVue®, FemCerv®, and FemCath® – are compliant with the new European ...

Femasys is an Atlanta-based company that provides minimally invasive women's reproductive health solutions, which are manufactured in the U.S. Later this week, the Company will be displaying its four commercially available products: FemaSeed® – FDA-cleared, intratubal insemination; FemVue® – contrast-generating device; FemCath® – selective delivery catheter; FemCerv® – endocervical tissue sampler; and its current lead product candidate in late-stage clinical development FemBloc® – a non-surgical, non-hormon ...

ATLANTA, May 17, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of inoffice, accessible, and innovative therapeutic and diagnostic products, announces CEO and Founder Kathy LeeSepsick has met with staff from the White House Office of Science and Technology Policy (OSTP) to discuss the President and First Lady's Cancer Moonshot and the Company's FemCerv® product. According to The White ...

ATLANTA, May 16, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of inoffice, accessible, and innovative therapeutic and diagnostic products, announces CEO and Founder Kathy LeeSepsick met with the White House's Gender Policy Council (GPC) staff to discuss the Company's reproductive health products and the future of women's health in the United States. According to The White House, "The ...

ATLANTA, May 16, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of inoffice, accessible, and innovative therapeutic and diagnostic products, announces CEO and Founder Kathy LeeSepsick met with the White House's Gender Policy Council (GPC) staff to discuss the Company's reproductive health products and the future of women's health in the United States. According to The White House, "The ...